This Article Abstract Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Alert me to new issues of the journal Add to Saved Citations Download to citation manager Request Permissions Request Reprints Add to My Marked Citations Citing Articles Citing Articles via Google Scholar Citing Articles via Scopus Google Scholar Articles by Kirby, M. Search for Related Content Social Bookmarking                         What's this?

Initiating insulin in patients with type 2 diabetes within primary care

The Surgery, Nevells Road, Letchworth, Hertfordshire, SG6 4TS, UK, kirbym{at}globalnet.co.uk

This article considers the challenge of initiating insulin therapy in people with type 2 diabetes in a primary care setting. Professor Mike Kirby discusses the changing interface of primary and secondary care roles and the influence of guidelines, goals and targets. Issues of patient concern and selection of insulin regimen are also addressed.

Key Words: initiating insulin • type 2 • diabetes glargine.

References

• Amos AF, McCarty DJ, Zimmet P. The rising global burden of diabetes and its complications: estimates and projections to the year 2010. Diabet Med 1997;14(suppl 5):S1S85.
• Department of Health. National Service Framework for Diabetes: Delivery Strategy. London, UK: 2003.
• Department of Health. National Service Framework for Diabetes: Standards. London, UK: 2001.
• A Barnett AH, Capaldi B., Davies-Lyons M. et al. Expert opinion statement on the use of insulin therapy in patients with type 2 diabetes in primary care. Pract Diabetes Intern 2003;20:97-102.[CrossRef]
• Bailey CJ, Turner RC Metformin. N Engl J Med 1996;334:574-9.[Free Full Text]
• Lebovitz HE Alpha-glucosidase inhibitors. Endocrinol Metab Clin North Am 1997;26: 539-51.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
• Stratton IM, Adler AI, Neil HA et al. Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35): prospective observational study. BMJ 2000;321:405-12.[Abstract/Free Full Text]
• UK Prospective Diabetes Study (UKPDS) Group. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet 1998;352:837-53.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
• National Institute for Clinical Excellence. Inherited Clinical Guideline G: Management of Type 2 Diabetes - Management of Blood Glucose. London, UK, 2002.
• Barnett AH, Capaldi B., Farooqi A. et al. Treating to target in Type 2 Diabetes: from lifestyle change to insulin therapy. A consensus guideline. Modern Diabetes Management 2003;4:2-5.
• UK Prospective Diabetes Study (UKPDS) Group. 34. Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes. Lancet 1998;352:854-65.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
• Lepore M., Pampanelli S., Fanelli C. et al. Pharmacokinetics and pharmacodynamics of subcutaneous injection of long-acting human insulin analog glargine, NPH insulin, and ultralente human insulin and continuous subcutaneous infusion of insulin lispro. Diabetes 2000;49:2142-8.[Abstract/Free Full Text]
• Owens DR, Zinman B., Bolli GB Insulins today and beyond. Lancet 2001;358:739-46.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
• Rosenstock J., Schwartz SL, Clark CM, Jr. et al. Basal insulin therapy in type 2 diabetes: 28-week comparison of insulin glargine (HOE 901) and NPH insulin. Diabetes Care 2001;24:631-6.[Abstract/Free Full Text]
• Yki-Järvinen H., Dressler A., Ziemen M. Less nocturnal hypoglycemia and better postdinner glucose control with bedtime insulin glargine compared with bedtime NPH insulin during insulin combination therapy in type 2 diabetes. HOE 901/3002 Study Group. Diabetes Care 2000;23:1130-6.[Abstract/Free Full Text]
• Riddle MC, Rosenstock J., Gerich J. Treatment to target trial: randomized addition of glargine or human NPH insulin to oral therapy of type 2 diabetic patients. Diabetes Care 2003;26:3080-6.[Abstract/Free Full Text]
• Fritsche A., Schweitzer MA, Haring H. Glimepiride combined with morning insulin glargine, bedtime neutral protamine hagedorn insulin, or bedtime insulin glargine in patients with Type 2 diabetes. Ann Intern Med 2003;138:952-9.[Abstract/Free Full Text]
• National Institute for Clinical Excellence. Technology Appraisal Guidance - No. 53. Guidance on the Use of Long-Acting Insulin Analogues for Treatment of Diabetes- Insulin Glargine. London, UK: 2002.
• Lindholm A., Jacobsen LV Clinical pharmacokinetics and pharmacodynamics of insulin aspart. Clin Pharmacokinet 2001;40:641-59.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
• Feinglos MN, Thacker CH, English J., Bethel MA, Lane JD Modification of postprandial hyperglycemia with insulin lispro improves glucose control in patients with type 2 diabetes. Diabetes Care 1997;20:1539-42.[Abstract]

The British Journal of Diabetes & Vascular Disease, Vol. 4, No. 2, 122-125 (2004)
DOI: 10.1177/14746514040040021101


CiteULike    Complore    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter    What's this?

This Article Abstract Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Alert me to new issues of the journal Add to Saved Citations Download to citation manager Request Permissions Request Reprints Add to My Marked Citations Citing Articles Citing Articles via Google Scholar Citing Articles via Scopus Google Scholar Articles by Kirby, M. Search for Related Content Social Bookmarking                         What's this?